NO308984B1 - Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme - Google Patents

Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme Download PDF

Info

Publication number: NO308984B1
Authority: NO; Norway
Prior art keywords: lipid; carrier system; polar; mixture; amphiphatic
Prior art date: 1992-03-27

Application number

NO943543A

Other languages

English (en)

Norwegian (no)

Other versions

NO943543L (no

NO943543D0 (no

Inventor

Hokan Nyqvist

Gert Anders Ragnarsson

Per Tingvall

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-27

Filing date

1994-09-23

Publication date

2000-11-27

1994-09-23 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

1994-09-23 Publication of NO943543L publication Critical patent/NO943543L/no

1994-09-23 Publication of NO943543D0 publication Critical patent/NO943543D0/no

2000-11-27 Publication of NO308984B1 publication Critical patent/NO308984B1/no

Links

150000002632 lipids Chemical class 0.000 title claims abstract description 105
238000002360 preparation method Methods 0.000 title claims description 13
239000003937 drug carrier Substances 0.000 title 1
210000004400 mucous membrane Anatomy 0.000 claims abstract description 9
239000002904 solvent Substances 0.000 claims abstract description 9
239000000654 additive Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 69
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 18
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 15
230000000975 bioactive effect Effects 0.000 claims description 15
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 15
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
229960004194 lidocaine Drugs 0.000 claims description 9
239000003589 local anesthetic agent Substances 0.000 claims description 8
239000011159 matrix material Substances 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
239000002245 particle Substances 0.000 claims description 7
150000003904 phospholipids Chemical class 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 6
206010052428 Wound Diseases 0.000 claims description 5
208000027418 Wounds and injury Diseases 0.000 claims description 5
150000004665 fatty acids Chemical class 0.000 claims description 5
150000003626 triacylglycerols Chemical class 0.000 claims description 5
229930186217 Glycolipid Natural products 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 3
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
229940049918 linoleate Drugs 0.000 claims 1
229940049964 oleate Drugs 0.000 claims 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
230000003444 anaesthetic effect Effects 0.000 abstract description 6
238000009472 formulation Methods 0.000 description 39
239000000463 material Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
208000012266 Needlestick injury Diseases 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
125000005456 glyceride group Chemical group 0.000 description 7
238000000034 method Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
239000003814 drug Substances 0.000 description 5
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000008240 homogeneous mixture Substances 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000008347 soybean phospholipid Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
235000010469 Glycine max Nutrition 0.000 description 3
244000068988 Glycine max Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
210000005178 buccal mucosa Anatomy 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000004744 fabric Substances 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
-1 mono- Chemical class 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
230000008961 swelling Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical group CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
239000012612 commercial material Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003232 mucoadhesive effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
238000011197 physicochemical method Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000013464 silicone adhesive Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO943543A 1992-03-27 1994-09-23 Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme NO308984B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9200952A SE9200952D0 (sv)	1992-03-27	1992-03-27	Pharmaceutical carrier system containing defined lipids
PCT/SE1993/000257 WO1993019736A1 (en)	1992-03-27	1993-03-26	A pharmaceutical carrier system containing defined lipids

Publications (3)

Publication Number	Publication Date
NO943543L NO943543L (no)	1994-09-23
NO943543D0 NO943543D0 (no)	1994-09-23
NO308984B1 true NO308984B1 (no)	2000-11-27

Family

ID=20385758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943543A NO308984B1 (no)	1992-03-27	1994-09-23	Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme

Country Status (10)

Country	Link
US (1)	US5635205A (da)
EP (1)	EP0636020B1 (da)
JP (1)	JPH07508708A (da)
AT (1)	ATE179885T1 (da)
DE (1)	DE69324914T2 (da)
DK (1)	DK0636020T3 (da)
FI (1)	FI114140B (da)
NO (1)	NO308984B1 (da)
SE (1)	SE9200952D0 (da)
WO (1)	WO1993019736A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5665379A (en) *	1990-09-28	1997-09-09	Pharmacia & Upjohn Aktiebolag	Lipid particle forming matrix, preparation and use thereof
SE9402453D0 (sv) *	1994-07-12	1994-07-12	Astra Ab	New pharmaceutical preparation
DE4447287C1 (de) *	1994-12-30	1996-11-07	Cevc Gregor	Präparat zum Wirkstofftransport durch Barrieren
DE69511418T2 (de) *	1995-10-28	2000-03-30	B. Braun Melsungen Ag	Lokalanästhetika und/oder Zentralanalgetika enthaltende pharmazeutische Zusammensetzungen
AU6919598A (en) *	1997-04-17	1998-11-13	Dumex-Alpharma A/S	A novel bioadhesive drug delivery system based on liquid crystals
CA2304096C (en) *	1997-09-18	2003-09-09	Pacira Pharmaceuticals, Inc.	Sustained-release liposomal anesthetic compositions
AU752802C (en)	1997-11-14	2006-04-13	Pacira Pharmaceuticals, Inc.	Production of multivesicular liposomes
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
IL140899A0 (en)	1998-07-17	2002-02-10	Skyepharma Inc	Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
DE69912441T2 (de)	1998-08-19	2004-08-19	Skyepharma Canada Inc., Verdun	Injizierbare wässerige propofoldispersionen
DE69825495T2 (de)	1998-12-23	2005-07-28	Idea Ag	Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
WO2001001962A1 (en)	1999-07-05	2001-01-11	Idea Ag.	A method for the improvement of transport across adaptable semi-permeable barriers
SE0000730D0 (sv) *	2000-03-06	2000-03-06	Scotia Holdings Plc	Lipid carrier
AU2002322024B2 (en) *	2001-05-31	2008-05-08	Pacira Pharmaceuticals, Inc.	Encapsulation of nanosuspensions in liposomes and microspheres
US20040105881A1 (en)	2002-10-11	2004-06-03	Gregor Cevc	Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US8920843B2 (en) *	2007-11-07	2014-12-30	Svip5 Llc	Slow release of organic salts of local anesthetics for pain relief
US20140066481A1 (en) *	2010-04-01	2014-03-06	Pharmanest Ab	Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics
EP2846773A4 (en) *	2012-05-10	2015-12-30	Painreform Ltd	DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
CN105120839B (zh) *	2013-02-28	2020-07-28	湖州惠中济世生物科技有限公司	可注射长效局麻药半固体制剂及其组成成分
US10220093B2 (en)	2013-02-28	2019-03-05	Mira Pharma Corporation	Long-acting semi-solid lipid formulations
US10561606B2 (en)	2017-12-06	2020-02-18	Mira Pharma Corporation	Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en)	2017-12-06	2022-08-30	Mira Pharma Corporation	Injectable long-acting semi-solid gel formulations
US12151024B2 (en)	2021-01-22	2024-11-26	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en)	2021-01-22	2022-03-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en)	2021-01-22	2022-06-14	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en)	2021-01-22	2021-06-15	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
EP4415713A4 (en)	2021-10-14	2025-08-06	Pacira Pharmaceuticals Inc	MULTIVESICULAR LIPOSOME FORMULATIONS OF BUPIVACAINE AND THEIR USES
US12156940B1 (en)	2024-05-20	2024-12-03	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en)	2024-05-20	2025-03-18	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en)	2024-05-20	2025-04-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0753661B2 (ja) *	1984-03-08	1995-06-07	フアレスフアーマスーチカルリサーチエヌブイ	プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
GB8613811D0 (en) *	1986-06-06	1986-07-09	Phares Pharm Res Nv	Composition & method
US5059421A (en) *	1985-07-26	1991-10-22	The Liposome Company, Inc.	Preparation of targeted liposome systems of a defined size distribution
SE9003100D0 (sv) *	1990-09-28	1990-09-28	Kabivitrum Ab	Lipid formulation system

1992
- 1992-03-27 SE SE9200952A patent/SE9200952D0/xx unknown
1993
- 1993-03-26 WO PCT/SE1993/000257 patent/WO1993019736A1/en not_active Ceased
- 1993-03-26 DE DE69324914T patent/DE69324914T2/de not_active Expired - Fee Related
- 1993-03-26 DK DK93908232T patent/DK0636020T3/da active
- 1993-03-26 JP JP5517360A patent/JPH07508708A/ja active Pending
- 1993-03-26 EP EP93908232A patent/EP0636020B1/en not_active Expired - Lifetime
- 1993-03-26 AT AT93908232T patent/ATE179885T1/de not_active IP Right Cessation
- 1993-03-26 US US08/307,761 patent/US5635205A/en not_active Expired - Fee Related
1994
- 1994-09-23 NO NO943543A patent/NO308984B1/no not_active IP Right Cessation
- 1994-09-26 FI FI944441A patent/FI114140B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0636020A1 (en)	1995-02-01
EP0636020B1 (en)	1999-05-12
NO943543L (no)	1994-09-23
DK0636020T3 (da)	1999-11-15
FI944441A0 (fi)	1994-09-26
SE9200952D0 (sv)	1992-03-27
NO943543D0 (no)	1994-09-23
DE69324914T2 (de)	1999-12-09
US5635205A (en)	1997-06-03
JPH07508708A (ja)	1995-09-28
FI114140B (fi)	2004-08-31
WO1993019736A1 (en)	1993-10-14
FI944441L (fi)	1994-09-26
DE69324914D1 (de)	1999-06-17
ATE179885T1 (de)	1999-05-15

Legal Events

Date	Code	Title	Description
2005-11-14	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO308984B1 (no)	2000-11-27	Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme
US5665379A (en)	1997-09-09	Lipid particle forming matrix, preparation and use thereof
EP0767669B1 (en)	2001-06-27	New pharmaceutical preparation for pain management
EP0514506B1 (en)	1996-05-08	Lipid formulation system
US20020048596A1 (en)	2002-04-25	Preparation for the transport of an active substance across barriers
DE4447287C1 (de)	1996-11-07	Präparat zum Wirkstofftransport durch Barrieren
JPH09508414A (ja)	1997-08-26	二重層製剤
WO1985000011A1 (en)	1985-01-03	Microdroplets of water-insoluble drugs
JPH04505319A (ja)	1992-09-17	創傷、切傷および擦傷に対する治療剤のデリバリーとしてのリポソームの使用
CA3018670A1 (en)	2017-10-05	Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration
JPH03176425A (ja)	1991-07-31	脂肪乳剤
CN112190504A (zh)	2021-01-08	一种含有玫瑰精油的长效液体凝胶及其制备方法和应用
SK5382002A3 (en)	2002-09-10	Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g] isoquinoline-5,10-dione dimaleate
JPS63500456A (ja)	1988-02-18	薬剤に用いるミクロエマルジョン
HK1021622B (en)	2004-06-18	Preparation for the transport of an active substance across barriers
TW202510876A (zh)	2025-03-16	緩釋麻醉劑組成物及其製備方法
PL197939B1 (pl)	2008-05-30	Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna